Caracterización de eventos adversos de medicamentos antirretrovirales reportados al Programa de farmacovigilancia Bogotá D. C., 2008-2016
The human immunodeficiency virus (HIV) according to WHO, is defined as an infection that attacks the immune system of a living being that will gradually deteriorate called "immunodeficiency", this type of virus can be transmitted by maintaining relationships Vaginal, anal, or oral sex with...
- Autores:
-
Cruz Montaña, Luis Fernando
- Tipo de recurso:
- Trabajo de grado de pregrado
- Fecha de publicación:
- 2017
- Institución:
- Universidad de Ciencias Aplicadas y Ambientales U.D.C.A
- Repositorio:
- Repositorio Institucional UDCA
- Idioma:
- spa
- OAI Identifier:
- oai:repository.udca.edu.co:11158/718
- Acceso en línea:
- https://repository.udca.edu.co/handle/11158/718
- Palabra clave:
- Farmacovigilancia
Medicamentos antirretrovirales
Eventos adversos
Programa Distrital de Farmacovigilancia
Antirretrovirales -- Efectos secundarios
- Rights
- closedAccess
- License
- Derechos Reservados - Universidad de Ciencias Aplicadas y Ambientales
id |
RepoUDCA2_f271c888c2718d709ff8f5ef33a10de6 |
---|---|
oai_identifier_str |
oai:repository.udca.edu.co:11158/718 |
network_acronym_str |
RepoUDCA2 |
network_name_str |
Repositorio Institucional UDCA |
repository_id_str |
|
dc.title.spa.fl_str_mv |
Caracterización de eventos adversos de medicamentos antirretrovirales reportados al Programa de farmacovigilancia Bogotá D. C., 2008-2016 |
title |
Caracterización de eventos adversos de medicamentos antirretrovirales reportados al Programa de farmacovigilancia Bogotá D. C., 2008-2016 |
spellingShingle |
Caracterización de eventos adversos de medicamentos antirretrovirales reportados al Programa de farmacovigilancia Bogotá D. C., 2008-2016 Farmacovigilancia Medicamentos antirretrovirales Eventos adversos Programa Distrital de Farmacovigilancia Antirretrovirales -- Efectos secundarios |
title_short |
Caracterización de eventos adversos de medicamentos antirretrovirales reportados al Programa de farmacovigilancia Bogotá D. C., 2008-2016 |
title_full |
Caracterización de eventos adversos de medicamentos antirretrovirales reportados al Programa de farmacovigilancia Bogotá D. C., 2008-2016 |
title_fullStr |
Caracterización de eventos adversos de medicamentos antirretrovirales reportados al Programa de farmacovigilancia Bogotá D. C., 2008-2016 |
title_full_unstemmed |
Caracterización de eventos adversos de medicamentos antirretrovirales reportados al Programa de farmacovigilancia Bogotá D. C., 2008-2016 |
title_sort |
Caracterización de eventos adversos de medicamentos antirretrovirales reportados al Programa de farmacovigilancia Bogotá D. C., 2008-2016 |
dc.creator.fl_str_mv |
Cruz Montaña, Luis Fernando |
dc.contributor.advisor.spa.fl_str_mv |
Sabogal Carmona, Juan Sebastián |
dc.contributor.author.spa.fl_str_mv |
Cruz Montaña, Luis Fernando |
dc.subject.spa.fl_str_mv |
Farmacovigilancia Medicamentos antirretrovirales Eventos adversos |
topic |
Farmacovigilancia Medicamentos antirretrovirales Eventos adversos Programa Distrital de Farmacovigilancia Antirretrovirales -- Efectos secundarios |
dc.subject.lemb.spa.fl_str_mv |
Programa Distrital de Farmacovigilancia Antirretrovirales -- Efectos secundarios |
description |
The human immunodeficiency virus (HIV) according to WHO, is defined as an infection that attacks the immune system of a living being that will gradually deteriorate called "immunodeficiency", this type of virus can be transmitted by maintaining relationships Vaginal, anal, or oral sex with a person infected with HIV, another factor that influences HIV transmission is contaminated blood transfusions or perhaps the sharing of needles, syringes, or other sharp instruments previously in contact with a Positive person in HIV. On the other hand, it can also be transmitted from the mother to the child during the gestation, delivery and breastfeeding process When a patient is diagnosed with HIV, it is essential that they experience an immediate change in their lifestyle, diet, physical exercise and the most appropriate pharmacological treatment. Antiretrovirals are used as chronic treatments to control viral load and improve the immune system, but studies have shown that adverse events reported to the district pharmacovigilance program are high, taking into account that combinations of medications are also used that may increase the possibility Of interactions and adverse events in the patient. In the present study, it was possible to identify certain adverse reactions typical of antiretroviral drugs, which are of vital importance when evaluating and monitoring patients who are receiving antiretroviral treatment, the statistics issued by WHO and UNAIDS on the Prevalence of HIV disease among males. On the other hand it is evidenced that the majority of adverse reactions are of Serious Non-seriousness -Moderado by what is determined that there was the need to intervene professional health without causing greater risks on treated patients. Finally, it is emphasized that it is important that pharmacovigilance and pharmaceutical care programs must be further strengthened in order to propose alternatives that allow safe and effective management of patients who present adverse reactions and thus generate optimization and / Or reducing costs in health care as well as raising awareness and stressing the importance of pharmacy as the main actor in the acquisition, storage and dispensing of medicines as well as ratify the importance of the Pharmaceutical Chemist and his knowledge of the drug which gives The ability to provide support to patients and generate an education about the rational use of medicines. |
publishDate |
2017 |
dc.date.accessioned.spa.fl_str_mv |
2017-09-08T14:54:21Z |
dc.date.available.spa.fl_str_mv |
2017-09-08T14:54:21Z |
dc.date.issued.spa.fl_str_mv |
2017 |
dc.type.spa.fl_str_mv |
Trabajo de grado - Pregrado |
dc.type.coarversion.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
dc.type.coar.spa.fl_str_mv |
http://purl.org/coar/resource_type/c_7a1f |
dc.type.driver.spa.fl_str_mv |
info:eu-repo/semantics/bachelorThesis |
dc.type.version.spa.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.redcol.spa.fl_str_mv |
http://purl.org/redcol/resource_type/TP |
format |
http://purl.org/coar/resource_type/c_7a1f |
status_str |
publishedVersion |
dc.identifier.uri.spa.fl_str_mv |
https://repository.udca.edu.co/handle/11158/718 |
url |
https://repository.udca.edu.co/handle/11158/718 |
dc.language.iso.spa.fl_str_mv |
spa |
language |
spa |
dc.rights.spa.fl_str_mv |
Derechos Reservados - Universidad de Ciencias Aplicadas y Ambientales |
dc.rights.coar.fl_str_mv |
http://purl.org/coar/access_right/c_14cb |
dc.rights.uri.spa.fl_str_mv |
https://creativecommons.org/licenses/by-nc/4.0/ |
dc.rights.accessrights.spa.fl_str_mv |
info:eu-repo/semantics/closedAccess |
dc.rights.creativecommons.spa.fl_str_mv |
Atribución-NoComercial 4.0 Internacional (CC BY-NC 4.0) |
rights_invalid_str_mv |
Derechos Reservados - Universidad de Ciencias Aplicadas y Ambientales https://creativecommons.org/licenses/by-nc/4.0/ Atribución-NoComercial 4.0 Internacional (CC BY-NC 4.0) http://purl.org/coar/access_right/c_14cb |
eu_rights_str_mv |
closedAccess |
dc.format.spa.fl_str_mv |
pdf |
dc.coverage.spatial.spa.fl_str_mv |
Bogotá, Colombia |
dc.publisher.faculty.spa.fl_str_mv |
Facultad de Ciencias |
dc.publisher.program.spa.fl_str_mv |
Química Farmacéutica |
institution |
Universidad de Ciencias Aplicadas y Ambientales U.D.C.A |
bitstream.url.fl_str_mv |
https://repository.udca.edu.co/bitstreams/5043992c-388b-4957-827a-973130734884/download https://repository.udca.edu.co/bitstreams/d1772d9b-81ab-4a4e-9352-ada1eeaa8522/download https://repository.udca.edu.co/bitstreams/aa290abd-9a31-4f66-acaf-993d2835d533/download https://repository.udca.edu.co/bitstreams/ec6d779f-182f-41f8-a881-afc91f97d5f4/download https://repository.udca.edu.co/bitstreams/01193d4e-0466-438d-8aed-ae1bcb883958/download https://repository.udca.edu.co/bitstreams/68f007af-7414-4338-8fca-f34cb111cc2e/download |
bitstream.checksum.fl_str_mv |
7dfa969cdeb43707e377f065832aecdd 3aeb146c7ad1f509eb9d2e7c818ac825 7dfa969cdeb43707e377f065832aecdd 3aeb146c7ad1f509eb9d2e7c818ac825 e37d9ae31b84f127f90f8506f4c69473 a0e63c220dcaeb81a1a2d9647381f3e8 |
bitstream.checksumAlgorithm.fl_str_mv |
MD5 MD5 MD5 MD5 MD5 MD5 |
repository.name.fl_str_mv |
Repositorio - Universidad de Ciencias Aplicadas y Ambientales UDCA. |
repository.mail.fl_str_mv |
bdigital@metabiblioteca.com |
_version_ |
1814213161800171520 |
spelling |
Sabogal Carmona, Juan SebastiánCruz Montaña, Luis FernandoBogotá, Colombia2017-09-08T14:54:21Z2017-09-08T14:54:21Z2017https://repository.udca.edu.co/handle/11158/718The human immunodeficiency virus (HIV) according to WHO, is defined as an infection that attacks the immune system of a living being that will gradually deteriorate called "immunodeficiency", this type of virus can be transmitted by maintaining relationships Vaginal, anal, or oral sex with a person infected with HIV, another factor that influences HIV transmission is contaminated blood transfusions or perhaps the sharing of needles, syringes, or other sharp instruments previously in contact with a Positive person in HIV. On the other hand, it can also be transmitted from the mother to the child during the gestation, delivery and breastfeeding process When a patient is diagnosed with HIV, it is essential that they experience an immediate change in their lifestyle, diet, physical exercise and the most appropriate pharmacological treatment. Antiretrovirals are used as chronic treatments to control viral load and improve the immune system, but studies have shown that adverse events reported to the district pharmacovigilance program are high, taking into account that combinations of medications are also used that may increase the possibility Of interactions and adverse events in the patient. In the present study, it was possible to identify certain adverse reactions typical of antiretroviral drugs, which are of vital importance when evaluating and monitoring patients who are receiving antiretroviral treatment, the statistics issued by WHO and UNAIDS on the Prevalence of HIV disease among males. On the other hand it is evidenced that the majority of adverse reactions are of Serious Non-seriousness -Moderado by what is determined that there was the need to intervene professional health without causing greater risks on treated patients. Finally, it is emphasized that it is important that pharmacovigilance and pharmaceutical care programs must be further strengthened in order to propose alternatives that allow safe and effective management of patients who present adverse reactions and thus generate optimization and / Or reducing costs in health care as well as raising awareness and stressing the importance of pharmacy as the main actor in the acquisition, storage and dispensing of medicines as well as ratify the importance of the Pharmaceutical Chemist and his knowledge of the drug which gives The ability to provide support to patients and generate an education about the rational use of medicines.El virus de la inmunodeficiencia humana (VIH) según la OMS, está definido como una infección que ataca el sistema inmunitario de un ser vivo el cual va a presentar un deterioro gradual denominado "inmunodeficiencia", este tipo de virus puede ser transmitido por mantener relaciones sexuales vaginales, anales u orales con una persona infectada de dicho virus, otro factor que influye en la transmisión de VIH son las transfusiones de sangre contaminadas o quizás el uso compartido de agujas, jeringas u otros instrumentos punzantes que previamente hallan estado en contacto con una persona positivo en VIH. Por otra parte también puede transmitirse de la madre al hijo durante el proceso de gestación, el parto y la lactancia Cuando un paciente es diagnosticado con VIH es indispensable que este experimente un cambio inmediato de su estilo de vida, dieta, ejercicio físico y el tratamiento farmacológico más apropiado. Siendo tratamientos crónicos, para controlar la carga viral y mejorar el sistema inmunológico se emplean antiretrovirales, pero estudios han revelado que los eventos adversos reportados al programa distrital de farmacovigilancia son altos, teniendo en cuenta que adicionalmente se utilizan combinaciones de medicamentos que pueden aumentar la posibilidad de interacciones y eventos adversos en el paciente. En el presente trabajo se lograron identificar ciertas reacciones adversas propias de los medicamentos antirretrovirales las cuales son de vital importancia a la hora de evaluar y hacer seguimiento de los pacientes que están en tratamientos antirretrovirales, se confirma las estadísticas emitidas por la OMS y ONUSIDA sobre la prevalencia de la enfermedad VIH sobre el sexo masculino. Por otra parte se evidencia que la mayoría de reacciones adversas son de seriedad No serio –Moderado por lo que se determina que hubo la necesidad de intervenir profesional de la salud sin que causara mayores riesgos sobre los pacientes tratados. Por último se hace énfasis en que es importante que los programas de farmacovigilancia y atención farmacéutica se tienen que seguir fortaleciendo con el fin de proponer alternativas que permitan dar un manejo seguro y eficaz a los pacientes que presenten reacciones adversas y así generar una optimización y/o reducción de los costos en la atención en salud como también generar conciencia y recalcar la importancia de la farmacia como actor principal en la adquisición, almacenamiento y dispensación de medicamentos así como ratificar la importancia del Químico Farmacéutico y su conocimiento del medicamento el cual le da la capacidad para brindar un acompañamiento a los pacientes y generar una educación sobre uso racional de los medicamentos.PregradoQuímico(a) FarmacéuticopdfspaDerechos Reservados - Universidad de Ciencias Aplicadas y Ambientaleshttps://creativecommons.org/licenses/by-nc/4.0/info:eu-repo/semantics/closedAccessAtribución-NoComercial 4.0 Internacional (CC BY-NC 4.0)http://purl.org/coar/access_right/c_14cbFarmacovigilanciaMedicamentos antirretroviralesEventos adversosPrograma Distrital de FarmacovigilanciaAntirretrovirales -- Efectos secundariosCaracterización de eventos adversos de medicamentos antirretrovirales reportados al Programa de farmacovigilancia Bogotá D. C., 2008-2016Trabajo de grado - Pregradohttp://purl.org/coar/resource_type/c_7a1finfo:eu-repo/semantics/bachelorThesisinfo:eu-repo/semantics/publishedVersionhttp://purl.org/redcol/resource_type/TPhttp://purl.org/coar/version/c_970fb48d4fbd8a85Facultad de CienciasQuímica FarmacéuticaPublicationTEXTcaracterizacion de eventos adversos de medicamentos antirretrovirales reportados al programa de f.pdf.txtcaracterizacion de eventos adversos de medicamentos antirretrovirales reportados al programa de f.pdf.txtExtracted texttext/plain133566https://repository.udca.edu.co/bitstreams/5043992c-388b-4957-827a-973130734884/download7dfa969cdeb43707e377f065832aecddMD53THUMBNAILcaracterizacion de eventos adversos de medicamentos antirretrovirales reportados al programa de f.pdf.jpgcaracterizacion de eventos adversos de medicamentos antirretrovirales reportados al programa de f.pdf.jpgGenerated Thumbnailimage/jpeg3796https://repository.udca.edu.co/bitstreams/d1772d9b-81ab-4a4e-9352-ada1eeaa8522/download3aeb146c7ad1f509eb9d2e7c818ac825MD54TEXTcaracterizacion de eventos adversos de medicamentos antirretrovirales reportados al programa de f.pdf.txtcaracterizacion de eventos adversos de medicamentos antirretrovirales reportados al programa de f.pdf.txtExtracted texttext/plain133566https://repository.udca.edu.co/bitstreams/aa290abd-9a31-4f66-acaf-993d2835d533/download7dfa969cdeb43707e377f065832aecddMD53THUMBNAILcaracterizacion de eventos adversos de medicamentos antirretrovirales reportados al programa de f.pdf.jpgcaracterizacion de eventos adversos de medicamentos antirretrovirales reportados al programa de f.pdf.jpgGenerated Thumbnailimage/jpeg3796https://repository.udca.edu.co/bitstreams/ec6d779f-182f-41f8-a881-afc91f97d5f4/download3aeb146c7ad1f509eb9d2e7c818ac825MD54ORIGINALcaracterizacion de eventos adversos de medicamentos antirretrovirales reportados al programa de f.pdfcaracterizacion de eventos adversos de medicamentos antirretrovirales reportados al programa de f.pdfapplication/pdf1689822https://repository.udca.edu.co/bitstreams/01193d4e-0466-438d-8aed-ae1bcb883958/downloade37d9ae31b84f127f90f8506f4c69473MD51LICENSElicense.txtlicense.txttext/plain14812https://repository.udca.edu.co/bitstreams/68f007af-7414-4338-8fca-f34cb111cc2e/downloada0e63c220dcaeb81a1a2d9647381f3e8MD5511158/718oai:repository.udca.edu.co:11158/7182024-05-09 14:18:55.972https://creativecommons.org/licenses/by-nc/4.0/Derechos Reservados - Universidad de Ciencias Aplicadas y Ambientalesopen.accesshttps://repository.udca.edu.coRepositorio - Universidad de Ciencias Aplicadas y Ambientales UDCA.bdigital@metabiblioteca.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 |